Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control

PHASE4TerminatedINTERVENTIONAL

Enrollment

390

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Insulin Glargine

Insulin glargine administered subcutaneously once daily.

DRUG

Insulin Glulisine

Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c \>6.5%)

Trial Locations (1)

sanofi-aventis, US, Bridgewater